One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with primary biliary cholangitis (PBC), according to top-line data from a Phase 2b/3 clinical trial. The new findings mean that the Phase 2b/3 EPICS-III study (NCT05133336) — which included adults who did not […] The post New trial data show saroglitazar works to ease liver damage in PBC appeared first on Liver Disease News.| Liver Disease News – The Web's Daily Resource for Liver Disease News
A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function improves with treatment despite permanent scarring — in people with primary biliary cholangitis (PBC). That’s according to a new study from researchers in China that showed that higher blood LMR levels — denoting a less active […] The post Blood marker can predict liver function improvement in PBC appeared first on Liver Disease News.| Liver Disease News – The Web's Daily Resource for Liver Disease News
The Phase 1b/2a study will continue recruiting adults with PBC with cognitive difficulties and fatigue at sites in the U.K. and Europe.| Liver Disease News